



BIOCRYST SCHEDULED TO PRESENT AT SALOMON SMITH BARNEY HEALTH CARE CONFERENCE

Contact: BioCryst Pharmaceuticals, Inc. W. Randall Pittman, Chief Financial Officer A. K. Schleusner, Director of Corporate Communications & Investor Relations (205) 444-4600

BioCryst Scheduled to Present at Salomon Smith Barney Health Care Conference

Birmingham, Alabama - October 24, 2001 - BioCryst Pharmaceuticals, Inc. (Nasdaq NM: BCRX) today announced that Charles E. Bugg, Ph.D., BioCryst Chairman and CEO, will speak at the Salomon Smith Barney Health Care Conference on October 29, 2001 at 2:00 p.m. EDT. The conference is being held at The Plaza Hotel in New York City.

An audio-webcast of the presentation can be heard live over the Internet during the conference at <http://www.veracast.com/clientaccess/ssb/healthcare-2001/32111473.cfm>. For those unable to listen at the designated time, the archived webcast will remain available for a period of 30 days. Additional information on BioCryst, including press releases, can be accessed on the BioCryst website, www.biocryst.com.

Founded in 1986, BioCryst Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of pharmaceuticals for the treatment of viral, inflammatory/autoimmune and cardiovascular diseases and disorders. BioCryst's most advanced drug candidate, RWJ-270201 (formerly known as BCX-1812), is a neuraminidase inhibitor designed to treat and prevent viral influenza.

This press release contains forward-looking statements that involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, achievements and the timing of certain events to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, which identifies important factors that could cause the actual results to differ materially from those contained in the projections or forward-looking statements.